PeproMene Bio publishes Phase 1 CAR T results
Analysis based on 8 articles · First reported Jul 20, 2026 · Last updated Sep 08, 2026
The publication of positive Phase 1 data in a prestigious journal like The Lancet could enhance PeproMene Bio's credibility and valuation, potentially attracting investment and partnerships. The promising efficacy and safety profile of PMB-CT01 may also impact the competitive landscape for CAR T-cell therapies, affecting established players in the oncology space.
PeproMene Bio announced the publication in The Lancet of results from its Phase 1 clinical trial of PMB-CT01, a first-in-class BAFF-R-targeted CAR T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The trial demonstrated durable complete responses in 7 of 9 treated patients (80%), including 4 of 6 patients who had progressed after prior CD19-directed CAR T-cell therapy. All complete responses remained ongoing at data cutoff, with the longest lasting 35 months. The therapy showed a favorable safety profile, with all cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome events limited to Grade 1. Based on these results, the trial expanded from City of Hope to multiple additional medical centers across the United States. The first patient in the expansion phase, who had triple-hit high-grade B-cell lymphoma after CD19 CAR T failure, also achieved a complete response. The Institute for Follicular Lymphoma Innovation had committed up to $11 million in December 2024 to support clinical development. PeproMene Bio has licensed intellectual property from City of Hope.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard